A5045701610- Pancreatic and Hepatic Oncology Research
- Machine Learning in Healthcare
- Artificial Intelligence in Healthcare
- AI in cancer detection
- Colorectal Cancer Screening and Detection
- Cancer Genomics and Diagnostics
- Bioinformatics and Genomic Networks
- Cancer Immunotherapy and Biomarkers
- Medical Coding and Health Information
- Chronic Disease Management Strategies
- Peptidase Inhibition and Analysis
- Gene expression and cancer classification
- Global Cancer Incidence and Screening
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Genetic Associations and Epidemiology
- Parasitic infections in humans and animals
- Parasite Biology and Host Interactions
- Antimicrobial Peptides and Activities
- Genetic factors in colorectal cancer
- Microtubule and mitosis dynamics
- Cancer Mechanisms and Therapy
- Radiomics and Machine Learning in Medical Imaging
- Computational Drug Discovery Methods
- Vitamin D Research Studies
University of Copenhagen
2019-2024
Novo Nordisk Foundation
2019-2024
Pancreatic cancer is an aggressive disease that typically presents late with poor outcomes, indicating a pronounced need for early detection. In this study, we applied artificial intelligence methods to clinical data from 6 million patients (24,000 pancreatic cases) in Denmark (Danish National Patient Registry (DNPR)) and 3 (3,900 the United States (US Veterans Affairs (US-VA)). We trained machine learning models on sequence of codes histories tested prediction occurrence within incremental...
Abstract We present the Danish Disease Trajectory Browser (DTB), a tool for exploring almost 25 years of data from National Patient Register. In dataset comprising 7.2 million patients and 122 admissions, users can identify diagnosis pairs with statistically significant directionality combine them to linear disease trajectories. Users search one or more codes (ICD-10 classification) explore progression patterns via an array functionalities. For example, set trajectories be merged into...
To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination stereotactic body radiotherapy (SBRT) patients refractory metastatic pancreatic cancer (mPC).Between November 2016 and December 2019, mPC were randomly assigned 1:1 to SBRT 15 Gy nivolumab/ipilimumab stratified by performance status (ClinicalTrials.gov identifier: NCT02866383). The primary end point was rate (CBR), defined as percentage complete partial response (PR) stable disease, according RECIST 1.1....
BackgroundHealth care is experiencing a drive towards digitisation, and many countries are implementing national health data resources. Although range of cancer risk models exists, the utility on population level for stratification across types has not been fully explored. We aimed to close this gap by evaluating pan-cancer built electronic records Danish with validation in UK Biobank.MethodsIn retrospective modelling study, model development internal were derived from following registries:...
Abstract Pancreatic cancer is an aggressive disease that typically presents late with poor patient outcomes. There a pronounced medical need for early detection of pancreatic cancer, which can be addressed by identifying high-risk populations. Here we apply artificial intelligence (AI) methods to dataset 6 million records 24,000 cases in the Danish National Patient Registry (DNPR) and, comparison, three 3,900 United States Department Veterans Affairs (US-VA) healthcare system. In contrast...
OPINION article Front. Bioinform., 08 February 2023Sec. Data Visualization Volume 3 - 2023 | https://doi.org/10.3389/fbinf.2023.1112113
Pancreatic cancer is one of the deadliest types with poor treatment options. Better detection early symptoms and relevant disease correlations could improve pancreatic prognosis. In this retrospective study, we used symptom codes (ICD-10) from Danish National Patient Registry (NPR) encompassing 6.9 million patients 1994 to 2018,, whom 23,592 were diagnosed cancer. The registry included 18,523 these patients. To complement compare diagnosis deeper clinical data, a text mining approach extract...
Abstract Non-oncogene addiction (NOA) genes are essential for supporting the stress-burdened phenotype of tumours and thus vital their survival. Although NOA acknowledged to be potential drug targets, there has been no large-scale attempt identify characterise them as a group across cancer types. Here we provide first method identification conditional rewired neighbours using systems approach. Using copy number data expression profiles from The Cancer Genome Atlas (TCGA) performed...
Tuberculosis (TB) presents a serious health problem with approximately quarter of the world's population infected Mycobacterium tuberculosis (M. tuberculosis) in an asymptomatic latent state which 5-10% develops active TB at some point their lives. The antimicrobial protein cathelicidin has broad activity towards viruses and bacteria including M. tuberculosis. Vitamin D increases expression many cell types macrophages, it been suggested that vitamin D-mediated against is dependent on...
YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a secreted glycoprotein produced by various cell types including stromal, immune, and cancer cells. It contributes to progression through tumor-promoting inflammation has been shown inhibit the cytotoxicity of T NK lymphocytes. In vivo studies have demonstrated synergistic anti-cancer effects blocking YKL-40 in combination with immune checkpoint inhibitors (ICIs). Biomarkers for prediction response ICIs are highly needed. We...
The network topology of a protein interactome is shaped by the function each protein, making it resource functional knowledge in tissues and single cells. Today, this underused, as complete characterization has proved difficult for large interactomes. We apply matrix visualization decoding approach to physical dendritic cell, thereby characterizing its with no prior assumptions structure. discover 294 proteins, forming topological motifs called "bow-ties" that tie together majority observed...
Abstract Pancreatic cancer is one of the deadliest types with poor treatment options. Better detection early symptoms and relevant disease correlations could improve pancreatic prognosis. In this retrospective study, we used symptom codes (ICD-10) from Danish National Patient Registry (NPR) encompassing 8.1 million patients 1977 to 2018, whom 22,727 were diagnosed cancer. To complement compare these diagnosis deeper clinical data, a text mining approach extract free notes in electronic...
Summary Background Health care is experiencing a drive towards digitisation and many countries are implementing national health data resources. Digital medicine promises to identify individuals at elevated risk of disease who may benefit from screening or interventions. This particularly needed for cancer where early detection improves outcomes. While range models exists, the utility population-wide electronic databases stratification across types has not been fully explored. Methods We use...
554 Background: Pancreatic ductal adenocarcinoma remains one of the most lethal diseases. Investigating novel treatment strategies for patients with metastatic pancreatic cancer (mPC) is crucial. The purpose this phase II trial study was to evaluate clinical benefit nivolumab or without ipilimumab in combination stereotactic body radiotherapy (SBRT) mPC. Methods: Between November 2016 and December 2019, refractory mPC were randomly assigned 1:1 SBRT 15 Gy nivolumab/ipilimumab stratified by...
Abstract Pancreatic cancer is a leading cause of cancer-related deaths worldwide with increasing incidence. Early diagnosis pancreatic key challenge, as the disease typically detected at late stage. However, patients who present early-stage can be cured by combination surgery, chemotherapy and radiotherapy. Thus, better understanding risk factors for detection early stages has great potential to improve patient survival reduce overall mortality from this aggressive malignancy. Here we...
<h3>Background</h3> YKL-40, also known as chitinase-3 like-1 protein (CHI3L1), is a secreted glycoprotein produced by various cell types including stromal, immune, and cancer cells. It contributes to progression through tumor-promoting inflammation. YKL-40 has been shown inhibit the cytotoxic function of T NK lymphocytes, in vivo studies have demonstrated synergistic anti-cancer effects blocking combination with immune checkpoint inhibitors (ICIs). Biomarkers for prediction response ICIs are...